Fig 1: DKK3 plasma concentrations and their relationship with age, BMI and eGFR. (A) Frequency distribution of DKK3 plasma levels in the PREVEND cohort. (B–D) Two-way fractional polynomial regression plots (in red) with 95% confidence intervals (CI, in grey) showing the relationship of plasma Dickopf-3 (DKK3) concentrations with (B) age, (C) body mass index (BMI) and (D) estimated glomerular filtration rate (eGFR). DKK3 and eGFR values are log2 transformed.
Fig 2: Aplidin and analogs do not induce canonical unfolded protein response but downregulate vascular maturation factors VASH1 and DKK3. Three different branches of UPR, the master regulator GRP78/HSP5A, the IRE1a/XPB-1 s and PERK/CHOP/DDIT3 pathway were analyzed. In contrast to thapsigargin (10 nM), bortezomib (5 nM), Aplidin (5 nM) and analogs (10 nM) did not induce HSP5A gene expression (a) and splicing XPB1 within 24 h (b). c Only thapsigargin was able to increase GRP78 and XPB1 s protein as analyzed after 72 h by Western Blot. d DDIT3/CHOP was significant elevated on gene expression after 24 h in bortezomib, Aplidin and analog-treated cells. Aplidin and derivates did not display such an inductive response as observed for thapsigargin. e For analysis of vascular maturation factors HUVECs were incubated with bortezomib (5nM), Aplidin™ (5nM) or Aplidin analogs (each 10 nM) Western Blot analysis of VASH1 protein in cytosolic extracts of bortezomib, Aplidin™ and Aplidin analog-treated endothelial cells. Aplidin™ and analogs downregulated VASH1 and KDR protein levels after 24 h. f DKK-3 release from endothelial cells was reduced upon treatment with bortezomib, Aplidin™ or PM01215 and PM02781 after 72 h, as determined by a sandwich ELISA specific for human DKK-3. The means of one treatment group were compared to untreated control. The level of significance for the analysis was set at p < 0.05
Fig 3: Cardiac gene expression and plasma concentrations of ANP and DKK3 in three different heart failure (HF) mouse models. Included HF models are transverse aortic constriction (TAC) (top row), myocardial infarction (MI) (middle row) and an obese/hypertension mouse model with HF with preserved ejection fraction characteristics (HFD + AngII, bottom row). (A) Natriuretic peptide precursor type A (Nppa) left ventricular (LV) gene expression (left) and N-terminal pro-atrial natriuretic peptide (NT-proANP) plasma concentrations (right). Data on Nppa and NT-proANP have been published previously, 9 but are presented here for convenience. (B) Dickkopf-3 (Dkk3) gene expression (left) and DKK3 plasma concentrations (right). Gene expression values are corrected for 36b4 gene expression and presented as fold change. Bars represent means. Error bars represent standard errors of the mean. *P < 0.05 vs. sham or low fat diet. #P < 0.05 vs. HFD. AngII, angiotensin-II; HFD, high fat diet; LFD, low fat diet.
Supplier Page from R&D Systems, a Bio-Techne Brand for Dkk-3 ELISA